0000000000446901

AUTHOR

F Riccardi

showing 3 related works from this author

Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Adva…

2012

INTRODUCTION:: The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here. METHODS:: QoL was assessed at baseline and every 3 weeks during first-line, using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 and QLQ-lung cancer specific module (LC13). Mean changes from baseline within arms …

OncologyMaleerlotinibLung NeoplasmsHealth-related quality of lifeNSCLCchemotherapyDeoxycytidinelaw.inventionRandomized controlled trialQuality of lifelawCarcinoma Non-Small-Cell LungSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsSurveys and QuestionnaireQuality of life analysis of TORCHErlotinib HydrochloridePrognosishumanitiesOncologyResearch DesignAdvanced non–small-cell lung cancerCarcinoma Squamous CellFemaleErlotinibRandomized trialmedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPrognosiEGFRFirst-line treatmentfirst-line erlotinibsecond-line cisplatin/gemcitabine chemotherapyAdenocarcinomaNOFollow-Up StudieErlotinib HydrochlorideInternal medicineadvanced non-small-cell lung cancermedicineHumansLung cancerAdvanced non-small-cell lung cancer; Chemotherapy; EGFR; Erlotinib; First-line treatment; Health-related quality of life; Randomized trialQuality of life analysis of TORCH first-line erlotinib second-line cisplatin/gemcitabine chemotherapy advanced non-small-cell lung cancer.AgedNeoplasm StagingSalvage TherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryQuestionnaireCancerQuinazolinemedicine.diseaseInterim analysisGemcitabineGemcitabineSurgeryLung Neoplasmquality of lifeQuinazolinesCarcinoma Large CellCisplatinNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Latent tubercolosis infection in patients with cronic plaque psoriasis: evidence from the Italian Psocare Registry

2015

SummaryBackground The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in…

RegistrieMaletaiwanAntitubercular AgentsBiological Factorquantiferon-tb-goldAntitubercular AgentBiological FactorsexperienceResidence Characteristics80 and overPrevalenceRegistriesYoung adultriskAged 80 and overLatent TuberculosiLatent tuberculosispsoriasisMiddle AgedItalyFemaletubercolosistubercolosiAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young Adult; 2708Humanmedicine.drugAdultmedicine.medical_specialtyAdolescentchronic plaque psoriasisTuberculinconsensus statementtubercolosis; psoriasisDermatology.Young Adulttuberculosis infectionSettore MED/35Age DistributionLatent TuberculosisInternal medicinePsoriasismedicineAdalimumabfactor antagonistsHumansPsoriasisnecrosis-factor blockers; quantiferon-tb-gold; consensus statement; factor antagonists; systemic treatment; therapy; experience;taiwan; assay; risknecrosis-factor blockersSex DistributionAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young AdultPUVA TherapyAgedPsoriasiHistory of tuberculosistherapytuberculosis infection chronic plaque psoriasisItalian Psocare Registrybusiness.industryTuberculin TestOdds ratiosystemic treatmentassaymedicine.diseasebacterial infections and mycosesConfidence intervalSurgeryResidence CharacteristicChronic DiseaseItalian Psocare Registrybusiness2708
researchProduct

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

2011

Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage…

OncologyCancer ResearchLung NeoplasmsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentDiseasechemotherapyDeoxycytidinelaw.inventionCarboplatinRandomized controlled trialNon-small cell lung cancerlawCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsPostoperative radiotherapyStage (cooking)Non-Small-Cell LungSurveyVinorelbineOncologyChemotherapy AdjuvantAdjuvantmedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPaclitaxelnon-small cell lung cancer; adjuvant; Survey; chemotherapyVinblastineadjuvantInternal medicinemedicineHumansLung cancerNeoplasm StagingCisplatinAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryCarcinomamedicine.diseaseGemcitabineSurgeryAdjuvant chemotherapyRadiation therapyLung NeoplasmRegimenHealth Care SurveysAdjuvant chemotherapy; Non-small cell lung cancer; Postoperative radiotherapy; SurveyAdjuvant chemotherapy; Non-small cell lung cancer; Postoperative radiotherapy; Survey; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma Non-Small-Cell Lung; Chemotherapy Adjuvant; Cisplatin; Deoxycytidine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy Adjuvant; Vinblastine; Vinorelbine; Health Care Surveys; Oncology; Pulmonary and Respiratory Medicine; Cancer ResearchRadiotherapy AdjuvantCisplatinbusiness
researchProduct